ArticleBlood red cells & iron2026
Factors associated with hemoglobin response to hydroxyurea in patients with sickle cell disease.
Article in Blood red cells & iron, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Daprodustat augments red cell and γ-globin production in models of sickle cell disease.Blood red cells & iron · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic anemia is a hallmark of sickle cell disease (SCD) and contributes to morbidity and mortality. Pharmacological treatment options for chronic anemia in SCD are limited. Hydroxyurea (HU) remains the gold standard SCD treatment, but conflicting data exist regarding the impact of HU on hemoglobin (Hb) level. We conducted a longitudinal study of Hb response after HU initiation in a cohort of 82 patients with SCD. We found that the mean Hb level increased by 0.4 g/dL at 1 month and 0.3 g/dL at 3 months after HU initiation, compared with baseline. An Hb increase of ≥1 g/dL was observed in 26.3% of participants at 1 month and in 21.6% at 3 months. We also assessed the baseline demographic, clinical, and laboratory markers that were associated with Hb response after HU initiation using univariate linear regression and multivariate linear mixed-effects modeling. Lower baseline Hb, male sex, younger age, and less severe genotype were independently associated with greater Hb increase in response to HU. The effects of sex and genotype severity on Hb response were not evident in unadjusted analyses. Our results suggest that HU monotherapy is insufficient to address chronic anemia in many patients with SCD and highlight the need for combination therapy with HU to improve anemia-related outcomes. Our study also demonstrates the feasibility of using baseline data to guide therapy selection and create individualized treatment plans for patients with SCD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.